Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome
- PMID: 35122116
- PMCID: PMC8816310
- DOI: 10.1007/s00281-022-00916-w
Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome
Abstract
Antiphospholipid syndrome (APS) is an autoimmune thrombophilia propelled by circulating antiphospholipid antibodies that herald vascular thrombosis and obstetrical complications. Antiphospholipid antibodies recognize phospholipids and phospholipid-binding proteins and are not only markers of disease but also key drivers of APS pathophysiology. Thrombotic events in APS can be attributed to various conspirators including activated endothelial cells, platelets, and myeloid-lineage cells, as well as derangements in coagulation and fibrinolytic systems. Furthermore, recent work has especially highlighted the role of neutrophil extracellular traps (NETs) and the complement system in APS thrombosis. Beyond acute thrombosis, patients with APS can also develop an occlusive vasculopathy, a long-term consequence of APS characterized by cell proliferation and infiltration that progressively expands the intima and leads to organ damage. This review will highlight known pathogenic factors in APS and will also briefly discuss similarities between APS and the thrombophilic coagulopathy of COVID-19.
Keywords: Antiphospholipid syndrome; Neutrophil extracellular traps; Thrombosis; Vasculopathy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
JSK received support from Jazz Pharmaceuticals for preclinical research. YK is an inventor on a pending patent (US20180369278A1) filed by the University of Michigan on the use of biogases in vascular disease.
Figures
References
-
- L. Riancho-Zarrabeitia, V. Martinez-Taboada, I. Rua-Figueroa, F. Alonso, M. Galindo-Izquierdo, J. Ovalles, A. Olive-Marques, A. Fernandez-Nebro, J. Calvo-Alen, R. Menor-Almagro, E. Tomero-Muriel, E. Uriarte-Isacelaya, A. Botenau, M. Andres, M. Freire-Gonzalez, G. Santos Soler, E. Ruiz-Lucea, M. Ibanez-Barcelo, I. Castellvi, C. Galisteo, V. Quevedo Vila, E. Raya, J. Narvaez-Garcia, L. Exposito, J.A. Hernandez-Beriain, L. Horcada, E. Aurrecoechea, J.M. Pego-Reigosa, Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality, Lupus 29(12) (2020) 1556–1565. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
